NCT06885671 Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy
| NCT ID | NCT06885671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | British Columbia Cancer Agency |
| Condition | Breast Cancer Early Stage Breast Cancer (Stage 1-3) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-06-08 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-06-08 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.
Eligibility Criteria
Inclusion Criteria: * Female participants age 40 or older * Able to provide informed consent * pTis-2 pN0 cM0 breast cancer, with tumor size \<3 cm as per provincial guidelines * Able to complete electronic or paper entry of participant reported outcomes independently or with assistance from caregiver/family/friend/research staff * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * A history and physical (clinical breast) examination, including ECOG performance status, performed within 8 weeks prior to enrollment. * Participant is judged able to: * Maintain a stable position during therapy * Tolerate immobilization device(s) that may be required to deliver PBI safely * Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date Exclusion Criteria: * History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years. * Uncontrolled concurrent malignant cancer * Seroma not visible * Ipsilateral implanted cardiac device * Prior radiotherapy requiring summation for planning. * Requirement for a radiation boost (as determined by the treating investigator) * Positive surgical margins * Surgical cavities lacking clear delineation (surgical clips are not required but may assist in target delineation) * Known germline BRCA1/2 mutation. * Serious medical comorbidities precluding radiotherapy (e.g., connective tissue disorders such as lupus or scleroderma) * Pregnant or breastfeeding
Contact & Investigator
Robert Olson, MD, MSc, FRCPC
PRINCIPAL INVESTIGATOR
BC Cancer - Prince George
Frequently Asked Questions
Who can join the NCT06885671 clinical trial?
This trial is open to female participants only, aged 40 Years or older, studying Breast Cancer Early Stage Breast Cancer (Stage 1-3). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06885671 currently recruiting?
Yes, NCT06885671 is actively recruiting participants. Contact the research team at rolson2@bccancer.bc.ca for enrollment information.
Where is the NCT06885671 trial being conducted?
This trial is being conducted at Prince George, Canada.
Who is sponsoring the NCT06885671 clinical trial?
NCT06885671 is sponsored by British Columbia Cancer Agency. The principal investigator is Robert Olson, MD, MSc, FRCPC at BC Cancer - Prince George. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.